206 related articles for article (PubMed ID: 27196756)
1. The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide.
Prekovic S; van Royen ME; Voet AR; Geverts B; Houtman R; Melchers D; Zhang KY; Van den Broeck T; Smeets E; Spans L; Houtsmuller AB; Joniau S; Claessens F; Helsen C
Mol Cancer Ther; 2016 Jul; 15(7):1702-12. PubMed ID: 27196756
[TBL] [Abstract][Full Text] [Related]
2. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
3. Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor.
Coleman DJ; Van Hook K; King CJ; Schwartzman J; Lisac R; Urrutia J; Sehrawat A; Woodward J; Wang NJ; Gulati R; Thomas GV; Beer TM; Gleave M; Korkola JE; Gao L; Heiser LM; Alumkal JJ
Oncotarget; 2016 Jun; 7(26):40690-40703. PubMed ID: 27276681
[TBL] [Abstract][Full Text] [Related]
4. Developing a Novel Enzalutamide-Resistant Prostate Cancer Model via AR F877L Mutation in LNCaP Cells.
Wang R; Ma S; Xu N; Gan Y; Li P; Zhang J; Zhang Z; Gu Q; Xiang J
Curr Protoc; 2024 Apr; 4(4):e1033. PubMed ID: 38652202
[TBL] [Abstract][Full Text] [Related]
5. A partially open conformation of an androgen receptor ligand-binding domain with drug-resistance mutations.
Doamekpor SK; Peng P; Xu R; Ma L; Tong Y; Tong L
Acta Crystallogr F Struct Biol Commun; 2023 Apr; 79(Pt 4):95-104. PubMed ID: 36995121
[TBL] [Abstract][Full Text] [Related]
6. Structural and molecular insights into the mechanism of resistance to enzalutamide by the clinical mutants in androgen receptor (AR) in castration-resistant prostate cancer (CRPC) patients.
Khan A; Mao Y; Tahreem S; Wei DQ; Wang Y
Int J Biol Macromol; 2022 Oct; 218():856-865. PubMed ID: 35905763
[TBL] [Abstract][Full Text] [Related]
7. Darolutamide as a Second-Generation Androgen Receptor Inhibitor in the Treatment of Prostate Cancer.
Abbasi A; Movahedpour A; Amiri A; Najaf MS; Mostafavi-Pour Z
Curr Mol Med; 2021; 21(4):332-346. PubMed ID: 32881669
[TBL] [Abstract][Full Text] [Related]
8. Molecular Dynamics Studies on the Enzalutamide Resistance Mechanisms Induced by Androgen Receptor Mutations.
Liu H; Wang L; Tian J; Li J; Liu H
J Cell Biochem; 2017 Sep; 118(9):2792-2801. PubMed ID: 28181296
[TBL] [Abstract][Full Text] [Related]
9. NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants.
Nadiminty N; Tummala R; Liu C; Yang J; Lou W; Evans CP; Gao AC
Mol Cancer Ther; 2013 Aug; 12(8):1629-37. PubMed ID: 23699654
[TBL] [Abstract][Full Text] [Related]
10. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
[TBL] [Abstract][Full Text] [Related]
11. Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth.
Kawahara T; Ide H; Kashiwagi E; El-Shishtawy KA; Li Y; Reis LO; Zheng Y; Miyamoto H
Urol Oncol; 2016 Oct; 34(10):432.e15-23. PubMed ID: 27330033
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor mutations for precision medicine in prostate cancer.
Shiota M; Akamatsu S; Tsukahara S; Nagakawa S; Matsumoto T; Eto M
Endocr Relat Cancer; 2022 Oct; 29(10):R143-R155. PubMed ID: 35900853
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer.
Anestis A; Sarantis P; Theocharis S; Zoi I; Tryfonopoulos D; Korogiannos A; Koumarianou A; Xingi E; Thomaidou D; Kontos M; Papavassiliou AG; Karamouzis MV
J Cancer Res Clin Oncol; 2019 May; 145(5):1221-1233. PubMed ID: 30805773
[TBL] [Abstract][Full Text] [Related]
15. Multivalent Peptoid Conjugates Which Overcome Enzalutamide Resistance in Prostate Cancer Cells.
Wang Y; Dehigaspitiya DC; Levine PM; Profit AA; Haugbro M; Imberg-Kazdan K; Logan SK; Kirshenbaum K; Garabedian MJ
Cancer Res; 2016 Sep; 76(17):5124-32. PubMed ID: 27488525
[TBL] [Abstract][Full Text] [Related]
16. Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.
Kregel S; Chen JL; Tom W; Krishnan V; Kach J; Brechka H; Fessenden TB; Isikbay M; Paner GP; Szmulewitz RZ; Vander Griend DJ
Oncotarget; 2016 May; 7(18):26259-74. PubMed ID: 27036029
[TBL] [Abstract][Full Text] [Related]
17. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D
Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525
[TBL] [Abstract][Full Text] [Related]
18. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).
Korpal M; Korn JM; Gao X; Rakiec DP; Ruddy DA; Doshi S; Yuan J; Kovats SG; Kim S; Cooke VG; Monahan JE; Stegmeier F; Roberts TM; Sellers WR; Zhou W; Zhu P
Cancer Discov; 2013 Sep; 3(9):1030-43. PubMed ID: 23842682
[TBL] [Abstract][Full Text] [Related]
19. Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells.
Rosati R; Chen B; Patki M; McFall T; Ou S; Heath E; Ratnam M; Qin Z
Mol Pharmacol; 2016 Sep; 90(3):225-37. PubMed ID: 27382012
[TBL] [Abstract][Full Text] [Related]
20. Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells.
Gaur S; Gross ME; Liao CP; Qian B; Shih JC
Prostate; 2019 May; 79(6):667-677. PubMed ID: 30693539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]